James Flynn's Insider Trades & SAST Disclosures
James Flynn's most recent trade in Lument Finance Trust Inc was a trade of 15,000 common stock done at an average price of $2.5 . Disclosure was reported to the exchange on May 16, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern James Flynn.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 2.52 per share. | 16 May 2025 | 15,000 | 313,220 (1%) | 0% | 2.5 | 37,790 | common stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 2.49 per share. | 16 May 2025 | 10,719 | 323,939 (1%) | 0% | 2.5 | 26,684 | common stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 22.00 per share. | 16 May 2025 | 175 | 325 | - | 22 | 3,850 | 7.875% Series A Cumulative Redeemable Preferred Stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 21.96 per share. | 16 May 2025 | 150 | 150 | - | 22.0 | 3,294 | 7.875% Series A Cumulartive Redeemable Preferred Stock |
| Larimar Therapeutics Inc | Flynn E James | Director, Ten Percent Owner, * Director by Deputization | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.64 per share. | 30 Apr 2025 | 4,402 | 16,702 (0%) | 0% | 43.6 | 192,103 | Class A Common |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,330 | 17,852 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,330 | 6,659 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,252 | 9,759 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,252 | 21,104 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 1,557 | 14,522 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 1,557 | 1,557 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 625 | 12,965 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 625 | 0 | - | - | Restricted Stock Units | |
| Synlogic Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2025 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 3,185 | 14,102 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 3,185 | 0 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.69 per share. | 01 Jul 2024 | 1,762 | 12,340 (0%) | 0% | 40.7 | 71,696 | Class A Common |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 13,011 | 13,011 | - | - | Restricted Stock Units | |
| Larimar Therapeutics Inc | Flynn E James | Director, Ten Percent Owner, * Director by Deputization | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 3,185 | 3,185 | - | - | Restricted Stock Units | |
| MEI Pharma Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 3.16 per share. | 16 May 2024 | 7,900 | 7,900 (0%) | 0% | 3.2 | 24,981 | Common Stock |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.57 per share. | 30 Apr 2024 | 3,594 | 10,917 (0%) | 0% | 37.6 | 135,027 | Class A Common |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 3,329 | 14,511 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 3,329 | 9,989 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 1,557 | 11,182 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 1,557 | 3,114 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 932 | 0 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 932 | 9,001 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 624 | 625 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 624 | 9,625 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Sale of securities on an exchange or to another person at price $ 38.82 per share. | 10 Apr 2024 | 6,114 | 8,069 (0%) | 0% | 38.8 | 237,345 | Class A Common |
| Synlogic Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2024 | 4,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Larimar Therapeutics Inc | Flynn James E | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 8.74 per share. | 16 Feb 2024 | 1,430,206 | 6,151,389 | - | 8.7 | 12,500,000 | Common Stock |
| Larimar Therapeutics Inc | James Flynn E | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 8.74 per share. | 16 Feb 2024 | 1,430,206 | 6,151,406 | - | 8.7 | 12,500,000 | Common Stock |
| Larimar Therapeutics Inc | E Flynn James | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 8.74 per share. | 16 Feb 2024 | 1,430,205 | 4,207,982 | - | 8.7 | 12,499,992 | Common Stock |
| Oruka Therapeutics Inc. | Flynn James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| MEI Pharma Inc | Flynn James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| MEI Pharma Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| MEI Pharma Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 6,700 | 6,700 | - | - | Stock Options (Right to Buy) | |
| MEI Pharma Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 6,700 | 6,700 | - | - | Stock Option (Right to Buy) | |
| John Wiley & Sons Inc. - O... | James J. Flynn | EVP & GM, Research & Learning | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2023 | 20,000 | 20,000 | - | - | Non-Qualified Stock Options (right to buy) | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 6,617 | 0 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 6,617 | 16,850 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.03 per share. | 30 Jun 2023 | 2,667 | 14,183 (0%) | 0% | 34.0 | 90,758 | Class A Common |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 13,318 | 13,318 | - | - | Restricted Stock Units | |
| Larimar Therapeutics Inc | Flynn James E | Director, Ten Percent Owner, * Director by Deputization | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2023 | 8,300 | 8,300 | - | - | Stock Option (Right to Buy) | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 1,556 | 4,671 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 1,556 | 11,789 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.21 per share. | 01 May 2023 | 1,556 | 10,233 (0%) | 0% | 38.2 | 59,455 | Class A Common |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 931 | 932 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 931 | 9,608 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 742 | 0 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 742 | 8,677 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 625 | 1,249 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 625 | 10,233 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 10,338 | 0 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 10,338 | 12,293 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.60 per share. | 09 Jan 2023 | 4,358 | 7,935 (0%) | 0% | 42.6 | 185,651 | Class A Common |
| Oruka Therapeutics Inc. | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 6,227 | 9,919 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 3,692 | 3,692 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.15 per share. | 02 May 2022 | 1,069 | 1,629 (0%) | 0% | 50.1 | 53,610 | Class A Common |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 931 | 931 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 931 | 5,686 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 741 | 1,672 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 741 | 742 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 624 | 1,874 | - | - | Restricted Stock Units | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 624 | 2,296 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 402 | 2,698 (0%) | 0% | 0 | Class A Common | |
| John Wiley & Sons Inc. - O... | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 402 | 0 | - | - | Restricted Stock Units | |
| Lument Finance Trust Inc | James P. Flynn | CEO | Purchase of securities on an exchange or from another person at price $ 2.82 per share. | 21 Mar 2022 | 13,500 | 298,220 (1%) | 0% | 2.8 | 38,081 | common stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | 11 Feb 2022 | 177,540 | 0 | - | - | Subscription Rights (right to buy) | ||
| Lument Finance Trust Inc | James P. Flynn | CEO | 11 Feb 2022 | 177,540 | 284,720 (1%) | 0% | 3.1 | 543,272 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges